Full Press Release Details
Alone or in Combination with Nivolumab in Patients with Non- Squamous NSCLC BA3011 AXL NSCLC December 4, 2023 BioAtla | Overview 1 confidential
Important Notices & Disclaimers This presentation (the
"Presentation") by BioAtla, Inc. ("we", "us", "our", "BioAtla", or the "Company") contains "forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995 relating to our business, operations and financial conditions, including but not limited to statements regarding business plans and prospects and whether our clinical trials will support registration; achievement of
milestones; results, conduct, progress and timing of our research and development programs and clinical trials; expectations with respect to enrollment and dosing in our clinical trials, plans and expectations regarding future data updates, clinical
trials, regulatory meetings and regulatory submissions; plans to form collaborations or other strategic partnerships for selected assets; the potential regulatory approval path for our product candidates; expectations about the sufficiency of our
cash and cash equivalents and plans to prioritize and focus development on selected assets and indications. Words such as, but not limited to, "anticipate", "believe", "could", "estimate",
"expect", "intend", "may", "plan", "potential", "predict", "project", "should", "will", "would" or the negative of those terms,
and similar expressions that convey uncertainty of future events or outcomes, identify forward-looking statements. These forward-looking statements reflect management's beliefs and views with respect to future events and are based on estimates
and assumptions as of the date of this Presentation and are subject to risks and uncertainties, including those described in the Company's filings with the SEC, including but not limited to the Company's latest Quarterly Report on Form 10-Q.
Moreover, the Company operates in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for management to predict all risks, nor can the Company assess the impact of all factors on its business
or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Given these uncertainties, you should not place undue reliance on these
forward-looking statements. The Company qualifies all the forward-looking statements in this Presentation by these cautionary statements. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking
statements, whether as a result of new information, future events or otherwise. Statements contained herein are made as of the date of this Presentation unless stated otherwise, and this Presentation shall not under any circumstances create an
implication that the information contained herein is correct as of any time after such date or that the information will be updated or revisited to reflect information that subsequently becomes available or changes occurring after that date hereof.
Certain information contained in this Presentation relates to or is based on statistical and other industry and market data obtained from independent industry publications and research, surveys and studies conducted by independent third parties as
well as the Company's own estimates of the prevalence of certain diseases and conditions. The market data used in this Presentation involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data.
Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information.
The Company's estimates of the patient population with the potential to benefit from treatment with any product candidates the Company may develop include several key assumptions based on its industry knowledge, industry publications and
third-party research, which may be based on a small sample size and may fail to accurately reflect the addressable patient population. While the Company believes that its internal assumptions are reasonable, no independent source has verified such
assumptions. This Presentation may contain trademarks, trade names, or service marks belonging to other entities. The Company does not intend the use or display of other parties' trade names, trademarks or service marks to imply a relationship
with, or endorsement or sponsorship of, or by these other parties. None of the Company or any of its directors, officers, employees, contractors, agents, consultants, advisors or other representatives makes any representation or warranty, express or
implied, as to the accuracy or completeness of the information contained in this Presentation.
Phase 2 BA3011 Non-Squamous NSCLC Monotherapy 1.8 mg/kg Q2W shows
encouraging efficacy signals Data Cut Date: 30Jun23 Prior PD-1/L1 treatment EGFR wild-type (N=15) Prior PD-1/L1 treatment (N=18) Best Overall Response, n (%) Confirmed PR 3 (20.0) 3 (16.7) Unconfirmed PR 2 (13.3) 2 (11.1) SD 7 (46.7) 10 (55.6) PD 2
(13.3) 2 (11.1) NA (early discontinuation due to AE) 1 (6.7) 1 (5.6) Response Rate n (%) 5 (33.3) 5 (27.8) Exact 95% CI 11.8, 61.6 9.7, 53.5 Disease Control Rate n (%) 8 (53.3) 10 (55.6) Exact 95% CI 26.6, 78.7 30.8, 78.5 Monotherapy median
Duration of Response was estimated to be 4.8 months with a range of 2.3-12.1+ months* * Combination therapy (n=17) : o Evaluable patients (majority with 4+ prior lines of therapy) received BA3011 + nivolumab o One patient experienced an
ongoing complete response (CR), 2 patients experienced PR, and 8 patients experienced stable disease (SD) BioAtla | Overview 13 *As of November 20, 2023
BA3011-002 NSCLC interim analysis BA3011 Monotherapy 1.8 mg/kg Q2W
confirmed BioAtla | Overview 14 Data Cut Date: 30Jun23
BA3011-002 NSCLC interim analysis BA3011 Monotherapy 1.8 mg/kg Q2W
BioAtla | Overview 15 Data Cut Date: 30Jun23
Summary of Treatment Emergent Adverse Events (non-squamous NSCLC) BA3011
BA3011 + Total monotherapy nivolumab (N=40) (n=23) (n=17) TEAEs with CTCAE grade 3 or 4 15 (65.2) 8 (47.1) 23 (57.5) Related grade 3 or 4 AEs 8 (34.8) 3 (17.6) 11 (27.5) Any serious TEAEs 9 (39.1) 5 (29.4) 14 (35.0) Related SAEs 3 (13.0) 1 (5.9) 4
(10.0) TEAEs leading to treatment d/c 1 (4.3) 1 (5.9) 2 (5.0) Related AEs leading to treatment d/c 1 (4.3) 1 (5.9) 2 (5.0) TEAEs leading to death 0 1 (5.9) 1 (2.5) Related AEs leading to death 0 0 0 BioAtla | Overview 19 Data Cut Date:
Treatment Emergent Adverse Events (Non-Squamous NSCLC) * Any grade
( 15% of patients) OR grade 3 ( 3% of patients) in the study population Preferred term TEAEs of any grade, n (%) TEAEs of grade 3, n (%) Fatigue 14 (35.0) 1 (2.5) Diarrhea 10 (25.0) 1 (2.5) Constipation 9 (22.5) 0 Decreased
appetite 9 (22.5) 1 (2.5) Anemia 8 (20.0) 2 (5.0) Nausea 8 (20.0) 0 Peripheral neuropathy 7 (17.5) 1 (2.5) Increased AST 7 (17.5) 3 (7.5) Dyspnea 6 (15.0) 2 (5.0) Neutropenia 6 (15.0) 2 (5.0) Increased ALT 5 (12.5) 3 (7.5) * No grade 4+ TEAEs among
most frequent. BioAtla | Overview 20 Data Cut Date: 30Jun23
BA3011 NSCLC Randomized Registrational Study Design Two Potentially
Registrational Paths Enabled via the FDA Type C Meeting nd 2 Line + Open-label; control: docetaxel Patients with NSCLC who have been previously treated with at least one prior line of therapy for metastatic disease Dual
primary endpoints: Progression Free Survival and Overall Survival rd 3 Line + Blinded; control: chemo monotherapy Patients with NSCLC who have been previously treated with at least two prior lines of therapy for metastatic disease
Primary endpoint: Overall Survival BioAtla | Overview 23